Interferon-induced hypopituitarism [3]

American Journal of Medicine

Volumn 114, Issue 2, 2003, Pages 161-163

  Concha, Lourdes B ^a   Carlson, Harold E ^a   Heimann, Alan ^a   Lake Bakaar, Gerond V ^a   Paal, Adam F ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ARGININE; GONADORELIN; HUMAN GROWTH HORMONE; HYDROCORTISONE; MESSENGER RNA; PROLACTIN; PROTIRELIN; RIBAVIRIN; SERMORELIN; SOMATOMEDIN C; TESTOSTERONE; THYREL; THYROTROPIN; THYROXINE;

ADULT; BRAIN; CASE REPORT; CLINICAL FEATURE; EMOTIONAL DISORDER; GROWTH HORMONE DEFICIENCY; HEPATITIS C; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; IMMUNE SYSTEM; LETTER; MALAISE; MALE; MEMORY; NEUROLOGIC EXAMINATION; NEUROPSYCHIATRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SELLA TURCICA; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; THYROID DISEASE; TREATMENT OUTCOME;

EID: 0037317911     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01323-2     Document Type: Letter

References (4)

1. Roti E., Minelli R., Giuberti T., et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-α Am J Med. 172:1996;482-487.
2. Sakane N., Yoshida T., Yoshioka K., et al. Re-versible hypopituitarism after interferon-α therapy. Lancet. 345:1995;1305.
3. Jorgensen J., Moller J., Skakkebaek N., et al. Thyroid function during growth hormone therapy. Horm Res. 38:1992;63-67.
4. Meyers C.A., Scheibel R., Forman A. Persistent neurotoxicity of systemically administered interferon-α Neurology. 41:1991;672-676.